Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Inflammatory Bowel Diseases

Free Subscription 18.05.2026 3 Aliment Pharmacol Ther 5 BMC Gastroenterol 1 Clin Exp Immunol 1 Clin Res Hepatol Gastroenterol 1 Gastroenterology 7 Inflamm Bowel Dis 8 J Crohns Colitis 1 J Pediatr 3 Lancet Gastroenterol Hepatol 2 Scand J Gastroenterol 1 Z Gastroenterol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Aliment Pharmacol Ther

1. GARCIA JLR, Suarez-Ferrer C, Zabana Y
   Letter: Early Inflammatory Benefit Is Not Yet Equivalent to Durable Surgical Advantage After Colectomy in Colonic Crohn's Disease. Authors' Reply.
   Aliment Pharmacol Ther. 2026 May 12. doi: 10.1111/apt.70715.
   PubMed        
   
   
2. BURR N
   Editorial: Inflammatory Bowel Disease Care Pathways-Improving Quality, but Not at Increased Cost.
   Aliment Pharmacol Ther. 2026 May 11. doi: 10.1111/apt.70726.
   PubMed        
   
   
3. GOYAL MK, Srivastava H, Sehgal T, Bishu S, et al
   Review Article: TL1A Inhibitors in IBD - Mechanistic Rationale and Clinical Evidence.
   Aliment Pharmacol Ther. 2026;63:1458-1473.
   PubMed         Abstract available
   
   

   
   BMC Gastroenterol

4. DAMJANOV D, Maletic JS, Petrovic T, Savic Z, et al
   Hepatitis E virus seroprevalence and infection status among patients with inflammatory bowel disease undergoing advanced therapy: a prospective single-center observational study.
   BMC Gastroenterol. 2026 May 12. doi: 10.1186/s12876-026-04907.
   PubMed         Abstract available
   
   
5. MACHADO MB, Vieira A, Orlandi SP, Xavier MO, et al
   Mapping the evolution of inflammatory bowel disease care in Brazil: a comparison of cross-sectional surveys from 2017 and 2023.
   BMC Gastroenterol. 2026 May 12. doi: 10.1186/s12876-026-04903.
   PubMed         Abstract available
   
   
6. WEI JJ, Hu YB, Li YF, Lu C, et al
   Efficacy and safety of dual biologics or combination therapy with JAK inhibitors in refractory inflammatory bowel disease: a retrospective single-center real-world study from China.
   BMC Gastroenterol. 2026 May 11. doi: 10.1186/s12876-026-04905.
   PubMed         Abstract available
   
   
7. HUANG J, Chen Z, Chen M, Zeng Z, et al
   Specific alterations in the gut microbiome and metabolome across disease locations of Crohn's disease: a systematic review.
   BMC Gastroenterol. 2026 May 11. doi: 10.1186/s12876-026-04898.
   PubMed         Abstract available
   
   
8. CHEN XJ, Guo Y, Peng H, Zhang HF, et al
   A gut vascular barrier damage-based scoring system predicts postoperative outcomes in Crohn's disease.
   BMC Gastroenterol. 2026 May 8. doi: 10.1186/s12876-026-04892.
   PubMed         Abstract available
   
   

   
   Clin Exp Immunol

9. SONMEZ G, Yaz I, Ustun C, Sahin A, et al
   SOCS1 Haploinsufficiency in a Patient with Granulomatous Interstitial Lung Disease and Inflammatory Bowel Disease-like Disease.
   Clin Exp Immunol. 2026 May 8:uxag023. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Clin Res Hepatol Gastroenterol

10. JAISWAL A, Arya M, Sharma DB
    Comments on "incidence and neoplastic risk associated with colonic stricture in paediatric-onset Crohn's disease: A population-based study".
    Clin Res Hepatol Gastroenterol. 2026;50:102840.
    PubMed        
    
    

    
    Gastroenterology

11. MEHTA-DHAND S, Hamidi N, Clarke AN, Hoentjen F, et al
    EFFECTIVENESS OF RISANKIZUMAB AFTER USTEKINUMAB FAILURE IN CROHN'S DISEASE: A MULTICENTER RETROSPECTIVE COHORT STUDY.
    Gastroenterology. 2026 May 8:S0016-5085(26)06830.
    PubMed        
    
    

    
    Inflamm Bowel Dis

12. FOULSER PFG, Martinez-Gili L, Balarajah S, Sundramoorthi R, et al
    Disease phenotype affects treatment of late-onset inflammatory bowel disease: Analysis of a large UK cohort.
    Inflamm Bowel Dis. 2026 May 8:izag072. doi: 10.1093.
    PubMed         Abstract available
    
    
13. PORTELA F, Ministro P, de Sousa HT, Roseira J, et al
    Soluble transferrin receptor as a reliable inflammation-independent marker of iron deficiency in Crohn's disease and ulcerative colitis.
    Inflamm Bowel Dis. 2026 May 9:izag057. doi: 10.1093.
    PubMed         Abstract available
    
    
14. ATREYA R, Neurath MF
    Authors' response to letter to editor-silencing GATA3: DNAzymes enter the therapeutic landscape of ulcerative colitis.
    Inflamm Bowel Dis. 2026 May 11:izag077. doi: 10.1093.
    PubMed        
    
    
15. ATREYA R, Kuhbacher T, Vieth M, Jefremow A, et al
    Targeting the transcription factor GATA3 by the DNAzyme formulation SB012 in patients with moderately-to-severely active ulcerative colitis: a multicenter, randomized, placebo-controlled, phase 2a induction trial.
    Inflamm Bowel Dis. 2026 May 12:izag046. doi: 10.1093.
    PubMed         Abstract available
    
    
16. 
    Correction to: Early Top-Down Treatment With Biologics Improves the Rates of Transmural Remission in Crohn's Disease-A Risk-Adjusted Propensity Score Matched Analysis.
    Inflamm Bowel Dis. 2026 May 13:izag084. doi: 10.1093.
    PubMed        
    
    
17. MEROLA E, La Rocca D, Scaglione M, Pes GM, et al
    The missing evidence: Stricturing Crohn's disease in clinical trials, a systematic review.
    Inflamm Bowel Dis. 2026 May 14:izag079. doi: 10.1093.
    PubMed         Abstract available
    
    
18. AZULAY A, Turner D
    Multi-omics-based machine learning model predicts response and guides treatment in Crohn's disease: a case study in nutritional therapy-response to editorial.
    Inflamm Bowel Dis. 2026 May 14:izag087. doi: 10.1093.
    PubMed        
    
    

    
    J Crohns Colitis

19. FRIEDMAN S, Zeiss K, Wod M, Nielsen J, et al
    Repeated opioid use during pregnancy in women with inflammatory bowel disease: prevalence and impact on birth outcomes in Denmark.
    J Crohns Colitis. 2026;20:jjag046.
    PubMed         Abstract available
    
    
20. NOOR NM, Zheng H, Cao Z, Caruso G, et al
    Bayesian prior elicitation on the efficacy of medical therapies in perianal fistulizing Crohn's disease.
    J Crohns Colitis. 2026;20:jjag061.
    PubMed         Abstract available
    
    
21. DANESE S, Dignass A, Laharie D, Limdi JK, et al
    Mirikizumab is associated with rapid and sustained improvements in novel measures of bowel urgency in moderately-to-severely active ulcerative colitis: 28-week results from the LUCENT-URGE trial.
    J Crohns Colitis. 2026;20:jjag049.
    PubMed         Abstract available
    
    
22. TRETON X, Stefanescu C, Mailhat C, Bouhnik Y, et al
    Crohn's Disease Activity Index in the era of obesity: time to abandon it?
    J Crohns Colitis. 2026;20:jjag050.
    PubMed         Abstract available
    
    
23. MEYER A, Bertrand A, Martin A, Carbonnel F, et al
    Comparative risk of serious infection in patients with ulcerative colitis treated with JAK inhibitors.
    J Crohns Colitis. 2026;20:jjag053.
    PubMed         Abstract available
    
    
24. MATHIAS RM, Bogatic D, Edwards L, Bibb L, et al
    Intestinal ultrasound reliably predicts fecal loading in patients with ulcerative colitis.
    J Crohns Colitis. 2026;20:jjag052.
    PubMed         Abstract available
    
    
25. PAPASOTIRIOU S, Hanauer SB
    Beyond the bowel: three rare complications of upadacitinib therapy in inflammatory bowel disease.
    J Crohns Colitis. 2026;20:jjag058.
    PubMed         Abstract available
    
    
26. MULDERS L, Pruijt M, Van Oostrom J, Van Der Zanden E, et al
    Hyperbaric oxygen therapy alters bowel perfusion and improves outcomes in patients with treatment-refractory ulcerative colitis: a prospective pilot trial.
    J Crohns Colitis. 2026;20:jjag065.
    PubMed         Abstract available
    
    

    
    J Pediatr

27. GADEPALLI S, Tribble A, Rahman M, Manning L, et al
    Antibiotic Utilization for Perianal Fistulizing Complications Among Young Patients with Crohn's Disease.
    J Pediatr. 2026 May 7:115142. doi: 10.1016/j.jpeds.2026.115142.
    PubMed         Abstract available
    
    

    
    Lancet Gastroenterol Hepatol

28. SOLITANO V, Jairath V, Magro F, Armuzzi A, et al
    Breaking the therapeutic ceiling in inflammatory bowel disease: myth or reality?
    Lancet Gastroenterol Hepatol. 2026 May 14:S2468-1253(26)00085.
    PubMed         Abstract available
    
    
29. VISSER E, Buskens CJ
    Appendicectomy: a disease-modifying treatment for ulcerative colitis? - Authors' reply.
    Lancet Gastroenterol Hepatol. 2026;11:447.
    PubMed        
    
    
30. ARDABILI AR, Mujagic Z, Agrawal M, Jess T, et al
    Appendicectomy: a disease-modifying treatment for ulcerative colitis?
    Lancet Gastroenterol Hepatol. 2026;11:446.
    PubMed        
    
    

    
    Scand J Gastroenterol

31. RESAL T, Lupas D, Keresztes C, Bacsur P, et al
    Predictive value of iron deficiency anaemia on the one-year disease course in inflammatory bowel disease patients in clinical and biochemical remission.
    Scand J Gastroenterol. 2026 May 11:1-9. doi: 10.1080/00365521.2026.2651163.
    PubMed         Abstract available
    
    
32. JIANG H, Ni C, Lin Z, Liu P, et al
    Incidence and prevalence of inflammatory Bowel disease in China: a regional population-based study from 2020 to 2022.
    Scand J Gastroenterol. 2026 May 11:1-9. doi: 10.1080/00365521.2026.2668430.
    PubMed         Abstract available
    
    

    
    Z Gastroenterol

33. HEISS J, Haziri D, Kolleck M, Lange K, et al
    When Behcet Mimics Crohn's disease: A Diagnostic Challenge.
    Z Gastroenterol. 2026 May 12. doi: 10.1055/a-2857-7832.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum